fbpx

Developmental disorders

Updated : September 3, 2022





Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

 
 

risperidone 

Indicated for autism:

<5 years: Safety and efficacy not established
5-16 years(<20kg)
Initial dose:0.25mg orally once a day
Titration: A following dose increase may be made in increments of 0.25 mg at intervals of 2 weeks or more, as tolerated, after a minimum of 4 days
Maintain this dose for a minimum of 14 days

5-16 years(>20kg)
Initial dose:0.5mg orally once a day
Titration: A following dose increase may be made in increments of 0.5 mg at intervals of 2 weeks or more, as tolerated, after a minimum of 4 days
Maintain this dose for a minimum of 14 days



Dose Adjustments


Renal impairment
Dosage adjustments may be necessary for mild to moderate renal impairment, but no specific guidelines have been provided. Caution is recommended. For severe renal impairment, the initial starting dose is 0.5 mg twice daily, with increments of 0.5 mg or less administered twice a day. For doses above 1.5 mg twice daily, increase in 1 week or more significant intervals. The long-acting intramuscular injection can be used if a total daily oral dose of at least 2 mg once daily is well tolerated, with an initial dose of 25 mg every two weeks by deep intramuscular injection in the deltoid or gluteal muscle

Liver impairment
Dosage adjustments may be necessary for mild to moderate hepatic dysfunction (Child-Pugh less than 10), but no specific guidelines have been provided. Caution is recommended. For severe hepatic dysfunction (Child-Pugh 10 to 15), the initial starting dose is 0.5 mg twice a day, with increments of 0.5 mg or less, administered twice daily. For doses above 1.5 mg twice daily, increase in 1 week or more significant intervals. The long-acting intramuscular injection can be used if a total daily oral dose of at least 2 mg once daily is well tolerated, with an initial dose of 25 mg every two weeks by deep intramuscular injection in the deltoid or gluteal muscle

 

Media Gallary

References

Developmental disorders

Updated : September 3, 2022




risperidone 

Indicated for autism:

<5 years: Safety and efficacy not established
5-16 years(<20kg)
Initial dose:0.25mg orally once a day
Titration: A following dose increase may be made in increments of 0.25 mg at intervals of 2 weeks or more, as tolerated, after a minimum of 4 days
Maintain this dose for a minimum of 14 days

5-16 years(>20kg)
Initial dose:0.5mg orally once a day
Titration: A following dose increase may be made in increments of 0.5 mg at intervals of 2 weeks or more, as tolerated, after a minimum of 4 days
Maintain this dose for a minimum of 14 days



Dose Adjustments


Renal impairment
Dosage adjustments may be necessary for mild to moderate renal impairment, but no specific guidelines have been provided. Caution is recommended. For severe renal impairment, the initial starting dose is 0.5 mg twice daily, with increments of 0.5 mg or less administered twice a day. For doses above 1.5 mg twice daily, increase in 1 week or more significant intervals. The long-acting intramuscular injection can be used if a total daily oral dose of at least 2 mg once daily is well tolerated, with an initial dose of 25 mg every two weeks by deep intramuscular injection in the deltoid or gluteal muscle

Liver impairment
Dosage adjustments may be necessary for mild to moderate hepatic dysfunction (Child-Pugh less than 10), but no specific guidelines have been provided. Caution is recommended. For severe hepatic dysfunction (Child-Pugh 10 to 15), the initial starting dose is 0.5 mg twice a day, with increments of 0.5 mg or less, administered twice daily. For doses above 1.5 mg twice daily, increase in 1 week or more significant intervals. The long-acting intramuscular injection can be used if a total daily oral dose of at least 2 mg once daily is well tolerated, with an initial dose of 25 mg every two weeks by deep intramuscular injection in the deltoid or gluteal muscle